Flavoxate
Hydrochloride Tablets Market, By Medicine Type (Branded and Generic), By
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies), and By Region (North America, Latin America, Europe, Middle East,
Asia Pacific, Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 -
2027
Flavoxate hydrochloride is a
muscle relaxant with urinary antispasmodic properties. Flavoxate binds to the
muscarinic receptors which suppresses micturition reflex. It helps in modifying
micturition center in the brain stem by increasing capacity of the urinary
bladder. Therefore, this provides relief from dysuria, urgency, nocturia,
suprapubic pain, frequency, and incontinence. Manufacturers such as Epic Pharma
LLC, Perrigo Company PLC, Incepta Pharmaceuticals Ltd., Recordati S.p.A, and
others offer generic flavoxate hydrochloride tablets in the market.
Global Flavoxate Hydrochloride
Tablets Market Drivers
Key players are focusing on
manufacturing of drugs in the global flavoxate hydrochloride tablets market.
Several generic players have launched their products after the patent
expiration of Urispas in the year 2004, manufactured by Janssen
Pharmaceuticals, Inc. For instance, companies such as Paddock Laboratories LLC
and Epic Pharma LLC launched generic products for Urispas, which are cheaper
than branded products in the year 2004 and 2011, respectively.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3384
Increasing incidence of lower
urinary tract dysfunction such as prolonged micturition, incomplete bladder
emptying, and others are expected to support growth of the market. For
instance, according to a review article by Investigative and Clinical Urology,
2017, globally, around 10% of the geriatric population is suffering from urine
incontinency while it is estimated to reach 20% by 2050. According to the same
source, in South Korea, in population aged 70 years above, 48% of men and 12%
of women are expected to suffer from detrusor contractile dysfunction in 2017.
As per the Central Medicare and Medicaid Services (CMS), U.S., around US$ 8,800
million of flavoxate hydrochloride tablets have been consumed in the year 2017
by patients in U.S. suffering from insomnia. These factors are expected to
support the global flavoxate hydrochloride tablets market growth over the
forecast period.
Global Flavoxate Hydrochloride
Tablets Market Restraints
Following factors are expected to
restrain the global flavoxate hydrochloride tablets market growth over the
forecast period. New medicines have been introduced in the market which belong
to different chemical class than flavoxate hydrochloride which is expected to
restrain growth of the flavoxate hydrochloride market. For instance, Merck
& Co. Inc., received approval for Recabrio by U.S. Food and Drug
Administration (FDA) in the year 2019. Recabrio is the combination of three
different drugs i.e. Imipenem (antibacterial agent), Cilastatin (dehydropeptidase
inhibitor), and Relebactam (beta lactamase inhibitor), a multifunctional drug
useful for the treatment of urinary tract infection while flavoxate
hydrochloride is a muscle relaxant.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/flavoxate-hydrochloride-tablets-market-3384
Global Flavoxate Hydrochloride
Tablets Market Regional Analysis
North America is expected to hold
dominant position in the global flavoxate hydrochloride tablets market over the
forecast period, owing to the large customer base and increase in incidence of
lower urinary tract dysfunction. Increasing prevalence of lower urinary tract
dysfunction is expected to boost the North America flavoxate hydrochloride
tablets market growth. For instance, according to the article from
Neuroimmunology and Neuroinflammation, 2019, 291,000 individuals in the
U.S. were suffering from lower urinary
tract dysfunction due to spinal cord injury.
According to the Arab Journal of
Urology, 2019, in Europe 66% of women were suffering from lower urinary tract
dysfunction mainly due to reasons such as nocturia, urgency, and urinary tract
infections. According to the Hong Kong Medical journal, 2019, in Asia, around,
77.8% of men and 77.3% of women over the age of 40 suffer from mild degree of
lower urinary tract symptoms. The above factors are expected to support the
global flavoxate hydrochloride tablets market growth over the forecast period.
Global Flavoxate Hydrochloride
Tablets Market Key Players
Some of the key players operating
in the global flavoxate hydrochloride tablets market are Epic Pharma LLC,
Perrigo Company PLC, Manus Aktteva Biopharma LLP, Recordati S.p.A, Taj
Pharmaceuticals Ltd., Trumac Healthcare, Zhejiang CONBA Pharmaceutical co.,
ltd., Walter Bushnell, and Cipla Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3384
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment